| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,846,095 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
37,076 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$60,923 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kies Peter |
CFO |
• – – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,433 |
161,356 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-10 |
4 |
D |
$5.70 |
$209,908 |
D/D |
(36,826) |
1,288,313 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
105,700 |
1,325,139 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2020-03-10 |
4 |
AS |
$9.32 |
$32,620 |
D/D |
(3,500) |
825,110 |
|
345% |
|
| Weiner David B. |
Director |
– • – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,666 |
828,610 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-10 |
4 |
D |
$5.70 |
$5,546 |
D/D |
(973) |
82,900 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,812 |
83,873 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2020-03-09 |
4 |
AS |
$18.00 |
$63,000 |
D/D |
(3,500) |
816,944 |
|
175% |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-08 |
4 |
D |
$14.09 |
$96,967 |
D/D |
(6,882) |
81,061 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,900 |
87,943 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2020-03-08 |
4 |
D |
$14.09 |
$104,604 |
D/D |
(7,424) |
140,923 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,467 |
148,347 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-08 |
4 |
D |
$14.09 |
$390,251 |
D/D |
(27,697) |
1,219,439 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,700 |
1,247,136 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,667 |
820,444 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-05 |
4 |
D |
$9.80 |
$96,599 |
D/D |
(9,857) |
68,043 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,567 |
77,900 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2020-03-05 |
4 |
D |
$9.80 |
$96,207 |
D/D |
(9,817) |
126,880 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,567 |
136,697 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-05 |
4 |
D |
$9.80 |
$366,236 |
D/D |
(37,371) |
1,183,436 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
120,100 |
1,220,807 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2020-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,667 |
808,777 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2020-01-13 |
4 |
B |
$3.11 |
$69,975 |
D/D |
22,500 |
1,100,707 |
2.81 |
330% |
|
| Zoth Lota S |
Director |
– • – |
2020-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,090 |
4,090 |
|
- |
|
| Yarno Wendy L |
Director |
– • – |
2019-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,090 |
16,350 |
|
- |
|
505 Records found
|
|
Page 9 of 21 |
|
|
